<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>HYDROMORPHONE HYDROCHLORIDE- hydromorphone hydrochloride suppository </strong><br>Paddock Laboratories, LLC<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Hydromorphone<br> Hydrochloride<br> CII</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Hydromorphone hydrochloride (<span class="Bold">WARNING: </span>May be habit forming), a hydrogenated ketone of morphine, is a narcotic analgesic. It is available in:</p>
<p>Suppositories (for rectal administration) containing:</p>
<dl>
<dt> </dt>
<dd>3 mg hydromorphone hydrochloride in a cocoa butter base with silicone dioxide.</dd>
</dl>
<p>The structural formula of hydromorphone hydrochloride is:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bfbba46-1979-4797-a29e-d67718131686&amp;name=hydromorphone-01.jpg"><p class="MultiMediaCaption">M.W. 321.8</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Hydromorphone hydrochloride is a narcotic analgesic; its principal therapeutic effect is relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The precise mechanism of action of hydromorphone hydrochloride and other opiates is not known, although it is believed to relate to the existence of opiate receptors in the central nervous system. There is no intrinsic limit to the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of hydromorphone hydrochloride; like morphine, adequate doses will relieve even the most severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Clinically, however, dosage limitations are imposed by the adverse effects, primarily <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, which can result from high doses.</p>
<p>Hydromorphone hydrochloride has diverse additional actions. It may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, changes in mood and mental clouding, depress the respiratory center and the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center, stimulate the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> center, produce pinpoint constriction of the pupil, enhance parasympathetic activity, elevate cerebrospinal fluid pressure, increase biliary pressure, produce transient <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p>Generally, the analgesic action of parenterally administered hydromorphone hydrochloride is apparent within 15 minutes and usually remains in effect for more than five hours. The onset of action of oral hydromorphone hydrochloride is somewhat slower, with measurable <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> occurring within 30 minutes.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Hydromorphone hydrochloride is indicated for the relief of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> such as that due to:</p>
<table class="Noautorules" width="60%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><dl>
<dt> </dt>
<dd>Surgery</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span></dd>
<dt> </dt>
<dd><span class="Italics">(Soft tissue and bone)</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">Burns</span></dd>
</dl></td>
<td align="left"><dl>
<dt> </dt>
<dd>Cancer</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">Biliary Colic</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="201690" conceptname="Renal colic">Renal Colic</span></dd>
</dl></td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Hydromorphone hydrochloride is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydromorphone; in the presence of an intracranial lesion associated with <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>; and whenever ventilatory function is depressed (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, kyphoscoliosis, status asthmaticus).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>:</h2>
<p class="First">Hydromorphone hydrochloride produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by acting directly on brain stem respiratory centers. Hydromorphone hydrochloride also affects centers that control respiratory rhythm, and may produce irregular and periodic breathing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>:</h2>
<p class="First">The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions or a preexisting increase in intracranial pressure. Furthermore, narcotics produce effects which may obscure the clinical course of patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>Acute Abdominal Conditions:</h2>
<p class="First">The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Special Risk Patients:</h2>
<p class="First">Hydromorphone hydrochloride should be used with caution in elderly or debilitated patients and those with impaired renal or hepatic function, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison's disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>. As with any narcotic analgesic agent, the usual precautions should be observed and the possibility of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> should be kept in mind.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> Reflex:</h2>
<p class="First">Hydromorphone hydrochloride suppresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex; as with all narcotics, caution should be exercised when hydromorphone hydrochloride is used postoperatively and in patients with pulmonary disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>Usage in Ambulatory Patients:</h2>
<p class="First">Narcotics may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery; patients should be cautioned accordingly.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.4"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with hydromorphone hydrochloride may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When such combined therapy is contemplated, the dose of one or both agents should be reduced.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.5"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Hydromorphone hydrochloride has been shown to be teratogenic in hamsters when given in doses 600 times the human dose. There are no adequate and well-controlled studies in pregnant women. Hydromorphone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-6.6"></a><p></p>
<h2>Nonteratogenic Effects:</h2>
<p class="First">Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritablity and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal. Chlorpromazine 0.7 to 1.0 mg/kg q6h, phenobarbital 2 mg/kg q6h, and paregoric 2 to 4 drops/kg q4h, have been used to treat withdrawal symptoms in infants. The duration of therapy is 4 to 28 days, with the dosages decreased as tolerated.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-6.7"></a><p></p>
<h2>Labor and Delivery:</h2>
<p class="First">As with all narcotics, administration of hydromorphone hydrochloride to the mother shortly before delivery may result in some degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher doses are used.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydromorphone hydrochloride, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.9"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Central Nervous System:</h2>
<p class="First">Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Gastrointestinal System:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occur infrequently; they are more frequent in ambulatory than in recumbent patients. The antiemetic phenothiazines are useful in suppressing these effects; however, some phenothiazine derivatives seem to be antianalgesic and to increase the amount of narcotic required to produce <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief, while other phenothiazines reduce the amount of narcotic required to produce a given level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Prolonged administration of hydromorphone hydrochloride may produce <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Opiate agonist-induced increase in intraluminal pressure may endanger surgical anastomosis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Cardiovascular System:</h2>
<p class="First">Circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, peripheral <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have occurred after rapid intravenous injection. <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> may occur if a patient stands up suddenly after receiving an injection of hydromorphone hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Genitourinary System:</h2>
<p class="First">Ureteral spasm, spasm of vesical sphincters and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="RD"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>:</h2>
<p class="First">Hydromorphone hydrochloride produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by acting directly on brain stem respiratory centers. Hydromorphone hydrochloride also affects centers that control respiratory rhythm, and may produce irregular and periodic breathing. If significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, it may be antagonized by the use of naloxone hydrochloride. The usual adult dose of 0.4 to 0.8 mg given<span class="Italics"> intramuscularly or intravenously, </span>promptly reverses the effects of morphine-like opioid agonists such as hydromorphone hydrochloride. In patients who are physically dependent, small doses of naloxone may be sufficient not only to antagonize <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, but also to precipitate withdrawal phenomena. The dose of naloxone should therefore be adjusted accordingly in such patients. SInce the duration of action of hydromorphone hydrochloride may exceed that of the antagonist, the patient should be kept under continued surveillance; repeated doses of the antagonist may be required to maintain adequate respiration. Apply other supportive measures when indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Hydromorphone hydrochloride is a Schedule II narcotic. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of narcotics; therefore, hydromorphone hydrochloride should be prescribed and administered with caution. However, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is unlikely to develop when hydromorphone hydrochloride is used for a short time for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, usually assumes clinically significant proportions only after several weeks of continued narcotic use, although some mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop after a few days of narcotic therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, is manifested initially by a shortened duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>, and subsequently by decreases in the intensity of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. The rate of development of tolerance varies among patients.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms:</h2>
<p class="First">Serious overdosage with hydromorphone hydrochloride is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage, particularly the intravenous route, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Treatment:</h2>
<p class="First">Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to narcotics, including hydromorphone hydrochloride. Therefore, naloxone hydrochloride should be administered as described under<span class="Bold Italics"> Adverse Reactions </span>(see<span class="Italics"><a href="#RD"> <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></span>) in conjunction with ventilatory assistance.</p>
<p>Since the duration of action of hydromorphone hydrochloride may exceed that of the antagonist, the patient should be kept under continued surveillance; repeated doses of the antagonist may be required to maintain adequate respiration. An antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Hydromorphone Hydrochloride Suppositories (3 mg) may provide longer duration of relief which could obviate additional medication during the sleeping hours. The usual adult dose is one (1) suppository inserted rectally every 6 to 8 hours or as directed by physician.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Rectal Suppositories: 3 mg Suppositories</p>
<dl>
<dt> </dt>
<dd>Boxes of 6      NDC 0574-7224-06</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Hydromorphone Hydrochloride Suppositories should be stored in a refrigerator. Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">A Schedule CII Narcotic</span></p>
<p><span class="Bold">DEA Order Form Required</span></p>
<p>Manufactured By<br><span class="Bold">Perrigo</span><span class="Sup">®</span><br>Minneapolis, MN 55427<br>(01-12)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 3 mg Packet Label</h1>
<p class="First"><span class="Bold">Hydromorphone HCl 3 mg<br>Suppository</span><br>(01)10305747224069<br>Manufactured By Perrigo®<br>Minneapolis, MN 55427</p>
<p><span class="Bold"> CII</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 3 mg Packet Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bfbba46-1979-4797-a29e-d67718131686&amp;name=hydromorphone-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDROMORPHONE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">hydromorphone hydrochloride suppository</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0574-7224</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RECTAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROMORPHONE HYDROCHLORIDE</strong> (HYDROMORPHONE) </td>
<td class="formItem">HYDROMORPHONE HYDROCHLORIDE</td>
<td class="formItem">3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COCOA BUTTER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">BULLET</td>
<td class="formLabel">Size</td>
<td class="formItem">32mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0574-7224-06</td>
<td class="formItem">12  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 PACKET</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">01/31/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Paddock Laboratories, LLC
							(967694121)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Paddock Laboratories, LLC</td>
<td class="formItem"></td>
<td class="formItem">967694121</td>
<td class="formItem">MANUFACTURE(0574-7224)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>386c81ac-bf28-4ede-9055-623644d8d832</div>
<div>Set id: 1bfbba46-1979-4797-a29e-d67718131686</div>
<div>Version: 1</div>
<div>Effective Time: 20120817</div>
</div>
</div> <div class="DistributorName">Paddock Laboratories, LLC</div></p>
</body></html>
